Jia Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jia Xia has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Yingjie Xu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Le Zhang
Department of Pediatric Laboratory, Department of Neonatology, Wuxi Children’s Hospital, Wuxi Key Laboratory of Genetic and Metabolic Diseases in Children, Affiliated Children’s Hospital of Jiangnan University, Wuxi, China
2 shared publications- Shan Mou
Department of Nephrology, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications - Wen Yang
Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2 shared publications - Xiang Yu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2 shared publications Yingjian Zhu
Department of Urology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (9)
Transcriptomic analysis of palmitoylation-related genes reveals a preferential association with BCAA catabolism in adipose tissue from pediatric obesity
Background: Pediatric obesity is a major public health challenge with adverse effects on health and long-term metabolic outcomes. Although diet and genetic susceptibility contribute to obesity across the life course, pediatric obesity may be particularly influenced by early-life developmental and maternal factors. Protein palmitoylation is linked to lipid metabolism, but whether palmitoylation-related programs differ between pediatric and adult obesity remains unclear. Methods: We analyzed transcriptomic datasets from pediatric and adult obesity using differential expression analysis and weighted gene co-expression network analysis (WGCNA). Candidate genes were further evaluated in a juvenile high-fat diet-induced obesity mouse model and online obesity databases. Results: In both age groups, palmitoylation-related candidate common hub genes were significantly enriched in lipid metabolic pathways. However, pediatric-specific palmitoylation-related candidate common hub genes were prominently enriched in branched-chain amino acid (BCAA) metabolic and catabolic processes. Least absolute shrinkage and selection operator regression prioritized seven candidate genes. In the juvenile obesity model, four genes (Cldn2, Mccc2, Pcca, and Vdac2) were consistently downregulated in adipose tissue from obese offspring, correlating significantly with fat mass. Downregulation was less pronounced in obese adult mice, whereas total protein palmitoylation was markedly elevated in both age groups, with a greater increase in juveniles. Of the four genes, Mccc2 and Pcca were directly involved in BCAA catabolism, suggesting an association between BCAA metabolism and pediatric obesity. Conclusion: These findings provide a basis for future mechanistic studies of age-related differences in adipose tissue metabolism in obesity.
- 26 August 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (9)
Open AccessTranscriptomic analysis of palmitoylation-related genes reveals a preferential association with BCAA catabolism in adipose tissue from pediatric obesity
Background: Pediatric obesity is a major public health challenge with adverse effects on health and long-term metabolic outcomes. Although diet and genetic susceptibility contribute to obesity across the life course, pediatric obesity may be particularly influenced by early-life developmental and maternal factors. Protein palmitoylation is linked to lipid metabolism, but whether palmitoylation-related programs differ between pediatric and adult obesity remains unclear. Methods: We analyzed transcriptomic datasets from pediatric and adult obesity using differential expression analysis and weighted gene co-expression network analysis (WGCNA). Candidate genes were further evaluated in a juvenile high-fat diet-induced obesity mouse model and online obesity databases. Results: In both age groups, palmitoylation-related candidate common hub genes were significantly enriched in lipid metabolic pathways. However, pediatric-specific palmitoylation-related candidate common hub genes were prominently enriched in branched-chain amino acid (BCAA) metabolic and catabolic processes. Least absolute shrinkage and selection operator regression prioritized seven candidate genes. In the juvenile obesity model, four genes (Cldn2, Mccc2, Pcca, and Vdac2) were consistently downregulated in adipose tissue from obese offspring, correlating significantly with fat mass. Downregulation was less pronounced in obese adult mice, whereas total protein palmitoylation was markedly elevated in both age groups, with a greater increase in juveniles. Of the four genes, Mccc2 and Pcca were directly involved in BCAA catabolism, suggesting an association between BCAA metabolism and pediatric obesity. Conclusion: These findings provide a basis for future mechanistic studies of age-related differences in adipose tissue metabolism in obesity.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1777367
Formononetin alleviated cisplatin-induced acute kidney injury by orchestrating renal tubular cell ferroptosis via PI3K/AKT/NRF2 pathway
Background: Cisplatin chemotherapy is limited by its nephrotoxicity, which leads to acute kidney injury (AKI). Ferroptosis is a key pathogenic mechanism in cisplatin-induced AKI. Formononetin (FN), a natural isoflavone, has demonstrated antioxidant and renoprotective potential, but its role in modulating ferroptosis remains unclear. Methods: A cisplatin-induced AKI model in mice and a cisplatin-injured HK-2 cell model were established. Kidney injury was assessed via serum creatinine, blood urea nitrogen, H&E staining, and Kim-1 expression. Ferroptosis was evaluated by measuring glutathione (GSH), malondialdehyde (MDA), iron deposition, lipid peroxidation, mitochondrial morphology, and the expression levels of GPX4, SLC7A11, FTH and FTL. The involvement of the NRF2 pathway was investigated using the inhibitor ML385 in vivo and siRNA in vitro . The role of the PI3K/AKT pathway was assessed using the inhibitor LY294002. Results: FN treatment significantly improved renal function and attenuated tubular damage in cisplatin-induced AKI. It suppressed key features of ferroptosis, as shown by increased GSH, decreased MDA and iron levels, and preserved mitochondrial integrity. FN also reduced the oxidized lipids, and reversed the cisplatin-induced downregulation of SLC7A11 and GPX4. The renoprotective and anti-ferroptotic effects of FN were abolished by the NRF2 inhibitor ML385 in vivo and by siRNA in vitro . Furthermore, FN activated the PI3K/AKT pathway, and the PI3K inhibitor LY294002 blocked FN-mediated upregulation of NRF2 and GPX4. Conclusion: FN protects against cisplatin-induced AKI by inhibiting ferroptosis. This effect is mechanistically associated with the activation of the PI3K/AKT pathway, which subsequently enhances NRF2 signaling and upregulates GPX4 expression. Our findings support FN as a potential candidate for further investigation in the prevention of cisplatin nephrotoxicity.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1777367
Open AccessFormononetin alleviated cisplatin-induced acute kidney injury by orchestrating renal tubular cell ferroptosis via PI3K/AKT/NRF2 pathway
Background: Cisplatin chemotherapy is limited by its nephrotoxicity, which leads to acute kidney injury (AKI). Ferroptosis is a key pathogenic mechanism in cisplatin-induced AKI. Formononetin (FN), a natural isoflavone, has demonstrated antioxidant and renoprotective potential, but its role in modulating ferroptosis remains unclear. Methods: A cisplatin-induced AKI model in mice and a cisplatin-injured HK-2 cell model were established. Kidney injury was assessed via serum creatinine, blood urea nitrogen, H&E staining, and Kim-1 expression. Ferroptosis was evaluated by measuring glutathione (GSH), malondialdehyde (MDA), iron deposition, lipid peroxidation, mitochondrial morphology, and the expression levels of GPX4, SLC7A11, FTH and FTL. The involvement of the NRF2 pathway was investigated using the inhibitor ML385 in vivo and siRNA in vitro . The role of the PI3K/AKT pathway was assessed using the inhibitor LY294002. Results: FN treatment significantly improved renal function and attenuated tubular damage in cisplatin-induced AKI. It suppressed key features of ferroptosis, as shown by increased GSH, decreased MDA and iron levels, and preserved mitochondrial integrity. FN also reduced the oxidized lipids, and reversed the cisplatin-induced downregulation of SLC7A11 and GPX4. The renoprotective and anti-ferroptotic effects of FN were abolished by the NRF2 inhibitor ML385 in vivo and by siRNA in vitro . Furthermore, FN activated the PI3K/AKT pathway, and the PI3K inhibitor LY294002 blocked FN-mediated upregulation of NRF2 and GPX4. Conclusion: FN protects against cisplatin-induced AKI by inhibiting ferroptosis. This effect is mechanistically associated with the activation of the PI3K/AKT pathway, which subsequently enhances NRF2 signaling and upregulates GPX4 expression. Our findings support FN as a potential candidate for further investigation in the prevention of cisplatin nephrotoxicity.
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Repair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Open AccessRepair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.
- Open Access
- 5 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1412
The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice
Neutralizing antibodies (nAbs), the popular antiviral drugs used for the treatment of COVID-19, are effective in reducing viral load and hospitalization. Currently, most nAbs are screened from convalescent or vaccinated individuals through single B-cell sequencing which requires cutting-edge facilities. Moreover, owing to the rapid mutation of SARS-CoV-2, some approved nAbs are no longer effective. In the present study, we designed a new approach to acquiring broadly neutralizing antibodies (bnAbs) from mRNA-vaccinated mice. Using the flexibility and speed of mRNA vaccine preparation, we designed a chimeric mRNA vaccine and sequential immunization strategies to acquire bnAbs in mice within a short period. By comparing different vaccination orders, we found that the initially administered vaccine had a greater effect on the neutralizing potency of mouse sera. Ultimately, we screened a strain of bnAb that neutralized wild-type, Beta, and Delta SARS-CoV-2 pseudoviruses. We synthesized the mRNAs of the heavy and light chains of this antibody and verified its neutralizing potency. This study developed a new strategy to screen for bnAbs in mRNA-vaccinated mice and identified a more effective immunization strategy for inducing bnAbs, providing valuable insights for future antibody drug development.
- 5 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1412
Open AccessThe Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice
Neutralizing antibodies (nAbs), the popular antiviral drugs used for the treatment of COVID-19, are effective in reducing viral load and hospitalization. Currently, most nAbs are screened from convalescent or vaccinated individuals through single B-cell sequencing which requires cutting-edge facilities. Moreover, owing to the rapid mutation of SARS-CoV-2, some approved nAbs are no longer effective. In the present study, we designed a new approach to acquiring broadly neutralizing antibodies (bnAbs) from mRNA-vaccinated mice. Using the flexibility and speed of mRNA vaccine preparation, we designed a chimeric mRNA vaccine and sequential immunization strategies to acquire bnAbs in mice within a short period. By comparing different vaccination orders, we found that the initially administered vaccine had a greater effect on the neutralizing potency of mouse sera. Ultimately, we screened a strain of bnAb that neutralized wild-type, Beta, and Delta SARS-CoV-2 pseudoviruses. We synthesized the mRNAs of the heavy and light chains of this antibody and verified its neutralizing potency. This study developed a new strategy to screen for bnAbs in mRNA-vaccinated mice and identified a more effective immunization strategy for inducing bnAbs, providing valuable insights for future antibody drug development.
- Open Access
- 4 September 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (9) , 1-15
Non-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation
Caspase-8 is a unique member of caspases with a dual role in cell death and survival. Caspase-8 expression is often lost in some tumors, but increased in others, indicating a potential pro-survival function in cancer. By analyzing transcriptome of enzalutamide-resistant prostate cancer cells, we found that resistance was conferred by a mild caspase-8 upregulation that in turn led to NF-κB activation and the subsequent upregulation of the downstream IL-8. Mechanistically, we found that the pro-survival and enzalutamide-resistance-promoting features of caspase-8 were independent of its proteolytic activity, using a catalytically-inactive caspase-8 mutant. We further demonstrated that caspase-8 pro-apoptotic function was inhibited via cFLIP binding. Moreover, high caspase-8 expression was correlated with a worse prognosis in prostate cancer patients. Collectively, our work demonstrates that enzalutamide-resistance is mediated by caspase-8 upregulation and the consequent increase in NF-κB/IL-8 mediated survival signaling, highlighting caspase-8 and NF-κB as potential therapeutic targets to overcome enzalutamide-resistance in CRPC.
- 4 September 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (9) , 1-15
Open AccessNon-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation
Caspase-8 is a unique member of caspases with a dual role in cell death and survival. Caspase-8 expression is often lost in some tumors, but increased in others, indicating a potential pro-survival function in cancer. By analyzing transcriptome of enzalutamide-resistant prostate cancer cells, we found that resistance was conferred by a mild caspase-8 upregulation that in turn led to NF-κB activation and the subsequent upregulation of the downstream IL-8. Mechanistically, we found that the pro-survival and enzalutamide-resistance-promoting features of caspase-8 were independent of its proteolytic activity, using a catalytically-inactive caspase-8 mutant. We further demonstrated that caspase-8 pro-apoptotic function was inhibited via cFLIP binding. Moreover, high caspase-8 expression was correlated with a worse prognosis in prostate cancer patients. Collectively, our work demonstrates that enzalutamide-resistance is mediated by caspase-8 upregulation and the consequent increase in NF-κB/IL-8 mediated survival signaling, highlighting caspase-8 and NF-κB as potential therapeutic targets to overcome enzalutamide-resistance in CRPC.